Prantik Das

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard, Laura Murphy, Noel W. Clarke et al. · The Lancet Oncology · 2023 · 102 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory et al. · The Lancet Oncology · 2023 · 81 citations · Full text

Medicine, Oncology, Pharmacology +11

Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial

Alison Birtle, Robert J. Jones, John Chester et al. · Journal of Clinical Oncology · 2024 · 80 citations · Full text

Medicine, Oncology, Surgery +15

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

Nicholas D. James, Noel W. Clarke, Adrian Cook et al. · International Journal of Cancer · 2022 · 77 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Chris Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2024 · 49 citations · Full text

Medicine, Oncology, Surgery +15